Ovarian Cancer risk factors and Their Mechanism of Action

Modinat Jolade Adaranijo, Christian Bach


Ovarian cancer continues to be one of the deadliest and lethal form of gynecological cancer affecting younger and older woman. Understanding various factors that could lead to ovarian cancer and how they are able to drive its progression, metastasis and survival might help in its treatment and prevention. This paper aims to review different risk factors both genetic and environmental that could lead to the development of ovarian cancer and their mechanism of action. The research methods used in this study follows the principles outlined by [1]. It is a comprehensive literature review on ovarian cancer risk factor. The role of genetics and environmental risk factors in ovarian carcinogenesis and their mechanism of action created a theoretical foundation of the paper. A new model is presented to encapsulate highly dynamic interaction between ovarian carcinogenesis and the mechanism of action of some associated risk factors. The contribution of the study is intended to review and summarize the theoretical and empirical knowledge that should inspire new discussions and directions for further research activity. The model highlights various factors that can trigger the development of ovarian cancer namely; TP53, BRCA genes, Cigarette smoke and Talc powder and how they are able to promote ovarian cancer. Various have been done about how mutation of certain genes and some environmental factors could lead to ovarian carcinogenesis. However, more research is needed to further understand how their mechanism of action. The content of this paper will be useful in devising a better screening, treatment and preventive measure towards the ovarian cancer. This study provides an exciting opportunity to advance our knowledge of ovarian cancer to efficiently aid medical practitioners and researchers to device better prevention and treatment plan to combat ovarian cancer.


Gynecological; Ovarian cancer; Mutation; Metastasis

Full Text:



J. Lepine and A. Wilcox-King, “Editors’ comments: Developing novel theoretical insight from reviews of existing theory and research,” Academy of Management Review, vol. 35, no. 4. pp. 506–509, 2010.

R. Palmirotta, E. Silvestris, S. D’Oronzo, A. Cardascia, and F. Silvestris, “Ovarian cancer: Novel molecular aspects for clinical assessment,” Crit. Rev. Oncol. Hematol., vol. 117, pp. 12–29, Sep. 2017.

L. M. S. Seeber and P. J. Van Diest, “Epigenetics in ovarian cancer,” Methods Mol. Biol., vol. 863, pp. 253–269, Aug. 2012.

D.-C. Le et al., “Reproductive factors in relation to ovarian cancer: a case–control study in Northern Vietnam,” Contraception, vol. 86, no. 5, pp. 494–499, Nov. 2012.

C. Vo and M. E. Carney, “Ovarian Cancer Hormonal and Environmental Risk Effect,” Obstetrics and Gynecology Clinics of North America. 2007.

P. G. Moorman et al., “Reproductive factors and ovarian cancer risk in African-American women,” Ann. Epidemiol., vol. 26, no. 9, pp. 654–662, Sep. 2016.

M. Petrillo et al., “BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study,” Am. J. Obstet. Gynecol., vol. 217, no. 3, p. 334.e1-334.e9, Sep. 2017.

J. Hu, Z. Liu, and X. Wang, “Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?” Med. Hypotheses, vol. 81, no. 4, pp. 515–520, Oct. 2013.

Y. Zhang, P. F. Coogan, J. R. Palmer, B. L. Strom, and L. Rosenberg, “Cigarette Smoking and Increased Risk of Mucinous Epithelial Ovarian Cancer,” Am. J. Epidemiol., vol. 159, no. 2, pp. 133–139, 2004.

P. K. Mills, D. G. Riordan, R. D. Cress, and H. A. Young, “Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California,” Int. J. Cancer.Journal Int. Du Cancer, vol. 112, no. 3, pp. 458–464, 2004.

S.-Y. Jeon, R.-E. Go, J.-R. Heo, C.-W. Kim, K.-A. Hwang, and K.-C. Choi, “Effects of cigarette smoke extracts on the progression and metastasis of human ovarian cancer cells via regulating epithelial-mesenchymal transition,” Reprod. Toxicol., vol. 65, pp. 1–10, Oct. 2016.

B. W. Stewart and C. P. Wild, “World cancer report 2014,” World Heal. Organ., pp. 1–2, 2014.

K. L. Bolton et al., “Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.,” JAMA, vol. 307, no. 4, pp. 382–90, 2012.

K. a Schrader et al., “Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.,” Obs. Gynecol, vol. 120, no. 2 Pt 1, pp. 235–40, 2012.

A. Toss et al., “Hereditary ovarian cancer: Not only BRCA 1 and 2 Genes,” BioMed Research International, vol. 2015. 2015.

A. J. Cole et al., “Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing,” Sci. Rep., vol. 6, no. 1, p. 26191, 2016.

M. Rechsteiner et al., “TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type,” Exp. Mol. Pathol., vol. 95, no. 2, pp. 235–241, Oct. 2013.

F. Salehi, L. Dunfield, K. P. Phillips, D. Krewski, and B. C. Vanderhyden, “Risk factors for ovarian cancer: An overview with emphasis on hormonal factors,” Journal of Toxicology and Environmental Health - Part B: Critical Reviews, vol. 11, no. 3–4. pp. 301–321, 2008.

C. Letter and J. Teixidor, “th 2017,” Br. J. Cancer, pp. 1–2, 2017.

E. E. Calle et al., “Ovarian cancer and smoking: Individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies,” Lancet Oncol., vol. 13, no. 9, pp. 946–956, Sep. 2012.

J. E. Muscat and M. S. Huncharek, “Perineal talc use and ovarian cancer: a critical review.,” Eur. J. Cancer Prev., vol. 17, no. 2, pp. 139–46, 2008.

M. A. Gates et al., “Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer,” Cancer Epidemiol. Biomarkers Prev., vol. 17, no. 9, pp. 2436–2444, 2008.

M. Huncharek, J. F. Geschwind, and B. Kupelnick, “Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: A meta-analysis of 11, 933 subjects from sixteen observational studies,” Anticancer Res., vol. 23, no. 2 C, pp. 1955–1960, 2003.

M. Huncharek and J. Muscat, “Perineal talc use and ovarian cancer risk: a case study of scientific standards in environmental epidemiology.,” Eur. J. Cancer Prev., vol. 20, no. 6, pp. 501–7, 2011.

D. M. Gertig et al., “Prospective Study of Talc Use and Ovarian Cancer,” JNCI J. Natl. Cancer Inst., vol. 92, no. 3, pp. 249–252, 2000.

S. Burghaus et al., “Genetic risk factors for ovarian cancer and their role for endometriosis risk,” Gynecol. Oncol., vol. 145, no. 1, pp. 142–147, Apr. 2017.

M. R. Jones, D. Kamara, B. Y. Karlan, P. D. P. Pharoah, and S. A. Gayther, “Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction,” Gynecol. Oncol., Oct. 2017.

Y. Natanzon, E. L. Goode, and J. M. Cunningham, “Seminars in Cancer Biology Epigenetics in ovarian cancer,” Semin. Cancer Biol., no. April, pp. 0–1, Aug. 2017.

W. P. Tew, “Ovarian cancer in the older woman,” Journal of Geriatric Oncology, vol. 7, no. 5. Elsevier, pp. 354–361, 01-Sep-2016.

A. Anagnostopoulos, S. E. Taylor, and J. M. Kirwan, “Ovarian cancer: current management and future directions,” Obstet. Gynaecol. Reprod. Med., vol. 25, no. 2, pp. 37–42, Feb. 2015.

U. A. Matulonis, A. K. Sood, L. Fallowfield, B. E. Howitt, J. Sehouli, and B. Y. Karlan, “Ovarian cancer,” Nat. Rev. Dis. Prim., vol. 2, p. 16061, 2016.

J. Hunn and G. C. Rodriguez, “Ovarian cancer: etiology, risk factors, and epidemiology.,” Clin. Obstet. Gynecol., vol. 55, no. 1, pp. 3–23, 2012.

X. Han and A. Jemal, “Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U.S.,” Am. J. Prev. Med., vol. 53, no. 4, pp. 504–507, 2017.

F. C. Nielsen, T. van Overeem Hansen, and C. S. Sørensen, “Hereditary breast and ovarian cancer: new genes in confined pathways,” Nat. Rev. Cancer, vol. 16, no. 9, pp. 599–612, 2016.

L. Andrews and D. G. Mutch, “Hereditary Ovarian Cancer and Risk Reduction,” Best Pract. Res. Clin. Obstet. Gynaecol., vol. 41, pp. 31–48, 2017.

V. Giannakeas et al., “A model for estimating ovarian cancer risk: Application for preventive oophorectomy,” Gynecol. Oncol., vol. 139, no. 2, pp. 242–247, 2015.

C. Corzo, M. D. Iniesta, M. G. Patrono, K. H. Lu, and P. T. Ramirez, “Role of Fallopian Tubes in the Development of Ovarian Cancer,” Journal of Minimally Invasive Gynecology, vol. 24, no. 2. pp. 230–234, 2017.

N. Wentzensen et al., “Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium,” J. Clin. Oncol., vol. 34, no. 24, pp. 2888–2898, 2016.

S. Sharma, S. Rajaram, T. Sharma, N. Goel, S. Agarwal, and B. D. Banerjee, “Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: A pilot study,” Int. J. Biochem. Mol. Biol., vol. 5, no. 1, pp. 1–10, 2014.

G. Liu et al., “Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.,” Pharmacogenomics, vol. 13, no. 13, pp. 1523–35, 2012.

L. Andrews and D. G. Mutch, “Hereditary Ovarian Cancer and Risk Reduction,” Best Pract. Res. Clin. Obstet. Gynaecol., vol. 41, no. January, pp. 1–18, May 2017.

K. Matsuo, K. E. Tierney, D. M. Schneider, P. Mhawech-Fauceglia, L. D. Roman, and D. M. Gershenson, “Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series,” Gynecol. Oncol. Reports, vol. 13, pp. 36–39, Aug. 2015.

A. Tutt and A. Ashworth, “The relationship between the roles of BRCA genes in DNA repair and cancer predisposition,” Trends in Molecular Medicine, vol. 8, no. 12. pp. 571–576, 2002.

P. L. Welcsh, K. N. Owens, and M. C. King, “Insights into the functions of BRCA1 and BRCA2,” Trends in Genetics, vol. 16, no. 2. pp. 69–74, 2000.

J. Lubinski et al., “Cancer variation associated with the position of the mutation in the BRCA2 gene,” Fam. Cancer, vol. 3, no. 1, pp. 1–10, 2004.

S. J. Ramus and S. A. Gayther, “The Contribution of BRCA1 and BRCA2 to Ovarian Cancer,” Molecular Oncology, vol. 3, no. 2. pp. 138–150, 2009.

C. Gorrini et al., “BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival,” J. Exp. Med., vol. 210, no. 8, pp. 1529–1544, 2013.

C. Gorrini et al., “Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway,” Proc. Natl. Acad. Sci., vol. 111, no. 12, pp. 4472–4477, 2014.

N. Li et al., “Nrf2 Is a Key Transcription Factor That Regulates Antioxidant Defense in Macrophages and Epithelial Cells: Protecting against the Proinflammatory and Oxidizing Effects of Diesel Exhaust Chemicals,” J. Immunol., vol. 173, no. 5, pp. 3467–3481, 2004.

B. A. Werness, “Ovarian Carcinoma In Situ With Germline BRCA1 Mutation and Loss of Heterozygosity at BRCA1 and TP53,” J. Natl. Cancer Inst., vol. 92, no. 13, pp. 1088–1091, 2000.

M. Aghmesheh et al., “No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers,” Gynecol. Oncol., vol. 95, no. 3, pp. 430–436, 2004.

K. V. Clark-Knowles, K. Garson, J. Jonkers, and B. C. Vanderhyden, “Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes,” Exp. Cell Res., vol. 313, no. 1, pp. 133–145, 2007.

K. Y. Kim, D. W. Park, E. B. Jeung, and K. C. Choi, “Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: Do they play a role in ovarian carcinogenesis?” J. Vet. Sci., vol. 11, no. 4, pp. 291–297, 2010.

M. Gasco, S. Shami, and T. Crook, “The p53 pathway in breast cancer.,” Breast Cancer Res., vol. 4, no. 2, pp. 70–76, 2002.

L. K. Mullany et al., “Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival,” Neoplasia, vol. 17, no. 10, pp. 789–803, Oct. 2015.

M. Murphy, D. T. McManus, P. G. Toner, and S. E. H. Russell, “TP53 mutation in ovarian carcinoma,” Eur. J. Cancer Part A, vol. 33, no. 8, pp. 1281–1283, Jul. 1997.

A. J. Levine and M. Oren, “The first 30 years of p53: growing ever more complex,” Nat. Rev. Cancer, vol. 9, no. 10, pp. 749–758, 2009.

Y. Aylon and M. Oren, “New plays in the p53 theater,” Current Opinion in Genetics and Development, vol. 21, no. 1. pp. 86–92, 2011.

Y. Yang-Hartwich et al., “p53 protein aggregation promotes platinum resistance in ovarian cancer,” Oncogene, vol. 34, no. 27, pp. 3605–3616, 2015.

M. Olivier, M. Hollstein, and P. Hainaut, “TP53 mutations in human cancers: origins, consequences, and clinical use.,” Cold Spring Harbor perspectives in biology, vol. 2, no. 1. 2010.

M. Olivier et al., “Li-Fraumeni and Related Syndromes: Correlation between Tumor Type, Family Structure, and TP53 Genotype,” Cancer Res., vol. 63, no. 20, pp. 6643–6650, 2003.

T. Kim et al., “p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2,” J. Exp. Med., vol. 208, no. 5, pp. 875–883, 2011.

P. Dong et al., “Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis,” Oncogene, vol. 32, no. 27, pp. 3286–3295, 2013.

J.-G. Lee, J.-H. Ahn, T. Jin Kim, J. Ho Lee, and J.-H. Choi, “Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals,” Sci. Rep., vol. 5, no. 1, p. 12642, 2015.

M. Zhang et al., “TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer,” Diagn. Pathol., vol. 12, no. 1, p. 16, 2017.

M. A. Rossing, K. L. Cushing-Haugen, K. G. Wicklund, and N. S. Weiss, “Cigarette smoking and risk of epithelial ovarian cancer.,” Cancer Causes Control, vol. 19, no. 4, pp. 413–20, 2008.

S. J. Jordan, D. C. Whiteman, D. M. Purdie, A. C. Green, and P. M. Webb, “Does smoking increase risk of ovarian cancer? A systematic review,” Gynecologic Oncology, vol. 103, no. 3. pp. 1122–1129, 2006.

D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. M. Wouters, “Systemic effects of smoking,” Chest, vol. 131, no. 5. pp. 1557–1566, 2007.

R. Talhout, T. Schulz, E. Florek, J. van Benthem, P. Wester, and A. Opperhuizen, “Hazardous compounds in tobacco smoke,” Int. J. Environ. Res. Public Health, vol. 8, no. 2, pp. 613–628, 2011.

J. O. Tweed, S. H. Hsia, K. Lutfy, and T. C. Friedman, “The endocrine effects of nicotine and cigarette smoke.,” Trends Endocrinol. Metab., vol. 23, no. 7, pp. 334–42, 2012.

United States Department of Health and Human Services, “The Health Consequences of Smoking—50 Years of Progress A Report of the Surgeon General,” A Rep. Surg. Gen., p. 1081, 2014.

D. Hanahan and R. A. Weinberg, “Review Hallmarks of Cancer: The Next Generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.

R. L. Coleman, “Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care,” Nat. Rev. Clin. Oncol., vol. 13, no. 2, pp. 71–72, 2015.

R. Zazenski et al., “Talc: Occurrence, Characterization, and Consumer Applications,” Regul. Toxicol. Pharmacol., vol. 21, no. 2, pp. 218–229, 1995.

P. K. Mills, D. G. Riordan, R. D. Cress, and H. a Young, “Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California.,” Int. J. Cancer, vol. 112, no. 3, pp. 458–64, 2004.

R. A. Baan, “Carcinogenic hazards from inhaled carbon black, titanium dioxide, and talc not containing asbestos or asbestiform fibers: Recent evaluations by an IARC Monographs Working Group,” in Inhalation Toxicology, 2007, vol. 19, no. SUPPL. 1, pp. 213–228.

K. L. Terry et al., “Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls,” Cancer Prev. Res., vol. 6, no. 8, pp. 811–821, 2013.

D. W. Cramer, A. F. Vitonis, K. L. Terry, W. R. Welch, and L. J. Titus, “The Association Between Talc Use and Ovarian Cancer,” Epidemiology, vol. 27, no. 3, pp. 334–346, 2016.

R. N. Grisham et al., “BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer,” Cancer, vol. 119, no. 3, pp. 548–554, 2013.

M. L. Gemignani et al., “Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma,” Gynecol. Oncol., vol. 90, no. 2, pp. 378–381, 2003.

D. Mayr, A. Hirschmann, U. Löhrs, and J. Diebold, “KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants,” Gynecol. Oncol., vol. 103, no. 3, pp. 883–887, 2006.

M. A. Merritt and D. W. Cramer, “Molecular pathogenesis of endometrial and ovarian cancer,” in Translational Pathology of Early Cancer, 2012, pp. 287–305.

M. K. McConechy et al., “Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles,” Mod. Pathol., vol. 27, no. 1, pp. 128–134, 2014.

T. Sharma et al., “Association of organochlorine pesticides and risk of epithelial ovarian cancer: A case control study,” J. Reprod. Heal. Med., vol. 1, no. 2, pp. 76–82, 2015.

C. L. Pearce et al., “Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies,” Lancet Oncol., vol. 13, no. 4, pp. 385–394, 2012.

E. Canaz, M. Kilinc, H. Sayar, G. Kiran, and E. Ozyurek, “Lead, selenium and nickel concentrations in epithelial ovarian cancer, borderline ovarian tumor and healthy ovarian tissues,” J. Trace Elem. Med. Biol., vol. 43, pp. 217–223, 2017.

A. Rabbani-Chadegani, S. Abdosamadi, N. Fani, and S. Mohammadian, “A comparison of the effect of lead nitrate on rat liver chromatin, DNA and histone proteins in solution,” Arch. Toxicol., vol. 83, no. 6, pp. 565–570, 2009.

K. Jomova and M. Valko, “Advances in metal-induced oxidative stress and human disease,” Toxicology, vol. 283, no. 2–3. pp. 65–87, 2011.

K. S. Kasprzak, F. W. Sunderman, and K. Salnikow, “Nickel carcinogenesis,” Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, vol. 533, no. 1–2. pp. 67–97, 2003.

A. Hartwig, L. H. F. Mullenders, R. Schlepegrell, U. Kasten, and D. Beyersmann, “Nickel(II) Interferes with the Incision Step in Nucleotide Excision Repair in Mammalian Cells,” Cancer Res., vol. 54, no. 15, pp. 4045–4051, 1994.

B. Govindarajan et al., “Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase.,” Mol. Med., vol. 8, no. 1, pp. 1–8, 2002.

R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA. Cancer J. Clin., vol. 67, no. 1, pp. 7–30, 2017.

T. Walsh et al., “Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing,” Proc. Natl. Acad. Sci., vol. 108, no. 44, pp. 18032–18037, 2011.

M. R. M. Hussain et al., “BRAF gene: From human cancers to developmental syndromes,” Saudi Journal of Biological Sciences, vol. 22, no. 4. pp. 359–373, 2015.

F. Giannandrea, L. Gandini, D. Paoli, R. Turci, and I. Figà-Talamanca, “Pesticide exposure and serum organochlorine residuals among testicular cancer patients and healthy controls.,” J. Environ. Sci. Health. B., vol. 46, no. 8, pp. 780–7, 2011.

DOI: http://dx.doi.org/10.24018/ejers.2018.3.2.617


  • There are currently no refbacks.

Copyright (c) 2018 Modinat Jolade Adaranijo, Christian Bach